Carbidopa/levodopa (WD-1603) vs Crexont (IPX203)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Carbidopa/levodopa (WD-1603)
Developed by Hong Kong WD Pharmaceutical Co., Limited
NCT05036473 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.
Reported efficacy
To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group. (27 days- from the baseline to the 27th day): Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) (met)
Result source: NCT05036473
Crexont (IPX203)
Marketed by Amneal Pharmaceuticals and partners
NCT03670953 · Phase 3 · completed
The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).
Next expected readout: February 2027 · NCT07138560 (registry estimate)
Reported efficacy
Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) (met)
Result source: NCT03670953
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Carbidopa/levodopa (WD-1603) | Crexont (IPX203) |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- Crexont (IPX203)
- —Not reported
ON time without troublesome dyskinesia, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- Crexont (IPX203)
- —Not reported
UPDRS Part III, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- Crexont (IPX203)
- —Not reported
MDS-UPDRS Part II, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- Crexont (IPX203)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Carbidopa/levodopa (WD-1603): 0 of 4 rows · Crexont (IPX203): 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Carbidopa/levodopa (WD-1603) | Crexont (IPX203) |
|---|---|---|
| Dropout rate | — | —IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result—IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Discontinued due to AEs | — | —IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result—IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Serious AEs | — | 2%IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result3.1%IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Most frequent reported AEs | — | dyskinesia 6.8% nausea 4.9% dry mouth 4.2% NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more resultnausea 4.3% anxiety 2.7% dizziness 2.3% NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Carbidopa/levodopa (WD-1603)
show 2 more results
Crexont (IPX203)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carbidopa/levodopa (WD-1603)'s landscape · Crexont (IPX203)'s landscape